Anesthesia and Circulating Tumor Cells in Primary Breast Cancer Patients: A Randomized Controlled Trial.

BACKGROUND The effect of anesthetic drugs on cancer outcomes remains unclear. This trial aimed to assess postoperative circulating tumor cell counts-an independent prognostic factor for breast cancer-to determine how anesthesia may indirectly affect prognosis. It was hypothesized that patients receiving sevoflurane would have higher postoperative tumor cell counts. METHODS The parallel, randomized controlled trial was conducted in two centers in Switzerland. Patients aged 18 to 85 yr without metastases and scheduled for primary breast cancer surgery were eligible. The patients were randomly assigned to either sevoflurane or propofol anesthesia. The patients and outcome assessors were blinded. The primary outcome was circulating tumor cell counts over time, assessed at three time points postoperatively (0, 48, and 72 h) by the CellSearch assay. Secondary outcomes included maximal circulating tumor cells value, positivity (cutoff: at least 1 and at least 5 tumor cells/7.5 ml blood), and the association between natural killer cell activity and tumor cell counts. This trial was registered with ClinicalTrials.gov (NCT02005770). RESULTS Between March 2014 and April 2018, 210 participants were enrolled, assigned to sevoflurane (n = 107) or propofol (n = 103) anesthesia, and eventually included in the analysis. Anesthesia type did not affect circulating tumor cell counts over time (median circulating tumor cell count [interquartile range]; for propofol: 1 [0 to 4] at 0 h, 1 [0 to 2] at 48 h, and 0 [0 to 1] at 72 h; and for sevoflurane: 1 [0 to 4] at 0 h, 0 [0 to 2] at 48 h, and 1 [0 to 2] at 72 h; rate ratio, 1.27 [95% CI, 0.95 to 1.71]; P = 0.103) or positivity. In one secondary analysis, administrating sevoflurane led to a significant increase in maximal tumor cell counts postoperatively. There was no association between natural killer cell activity and circulating tumor cell counts. CONCLUSIONS In this randomized controlled trial investigating the effect of anesthesia on an independent prognostic factor for breast cancer, there was no difference between sevoflurane and propofol with respect to circulating tumor cell counts over time. : WHAT WE ALREADY KNOW ABOUT THIS TOPIC: Anesthesia may contribute to the distant spread of cancer during surgical treatmentThe presence of circulating tumor cells has been independently associated with both a higher risk of disease recurrence and reduced survival in both nonmetastatic and metastatic breast cancer WHAT THIS ARTICLE TELLS US THAT IS NEW: The hypothesis that postoperative circulating tumor cell counts would be higher in primary breast cancer patients receiving sevoflurane anesthesia than in those receiving intravenous anesthesia with propofol was tested in a randomized controlled trial of 210 patientsThe type of anesthesia did not affect circulating tumor cell counts over time (median circulating tumor cell count/7.5 ml blood [interquartile range]: for propofol, 1 [0 to 4] at end of surgery (0 h), 1 [0 to 2] at 48 h, and 0 [0 to 1] at 72 h; and for sevoflurane, 1 [0 to 4] at 0 h, 0 [0 to 2] at 48 h, and 1 [0 to 2] at 72 h; rate ratio, 1.27 [95% CI, 0.95 to 1.71]).

[1]  E. Mascha,et al.  Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial , 2019, The Lancet.

[2]  W. Han,et al.  Total Intravenous Anesthesia versus Inhalation Anesthesia for Breast Cancer Surgery: A Retrospective Cohort Study , 2019, Anesthesiology.

[3]  A. Gavin,et al.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.

[4]  Yue-Cune Chang,et al.  Propofol-based Total Intravenous Anesthesia Is Associated with Better Survival Than Desflurane Anesthesia in Colon Cancer Surgery , 2018, Anesthesiology.

[5]  A. Schneeweiss,et al.  Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer , 2018, Breast Cancer Research and Treatment.

[6]  Tao Yan,et al.  Effects of propofol/remifentanil-based total intravenous anesthesia versus sevoflurane-based inhalational anesthesia on the release of VEGF-C and TGF-β and prognosis after breast cancer surgery: a prospective, randomized and controlled study , 2018, BMC Anesthesiology.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  S. Sleijfer,et al.  Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis , 2018, Journal of the National Cancer Institute.

[9]  T. Oh,et al.  Long-Term Oncologic Outcomes for Patients Undergoing Volatile Versus Intravenous Anesthesia for Non-Small Cell Lung Cancer Surgery , 2018, Cancer control : journal of the Moffitt Cancer Center.

[10]  E. Sloan,et al.  Perioperative events influence cancer recurrence risk after surgery , 2018, Nature Reviews Clinical Oncology.

[11]  Guonian Wang,et al.  Effects of propofol-based total intravenous anesthesia on gastric cancer: a retrospective study , 2018, OncoTargets and therapy.

[12]  P. Ferrari,et al.  Prognostic and predictive biomarkers in breast cancer: Past, present and future. , 2017, Seminars in cancer biology.

[13]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[14]  Leonie L. Zeune,et al.  Quantifying HER-2 expression on circulating tumor cells by ACCEPT , 2017, PloS one.

[15]  H. Kim,et al.  Impact of anesthetic agents on overall and recurrence-free survival in patients undergoing esophageal cancer surgery: A retrospective observational study , 2017, Scientific Reports.

[16]  J. Soria,et al.  RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. , 2017, European journal of cancer.

[17]  J. H. Lee,et al.  The Effects of Perioperative Anesthesia and Analgesia on Immune Function in Patients Undergoing Breast Cancer Resection: A Prospective Randomized Study , 2017, International journal of medical sciences.

[18]  M. Hollmann,et al.  Perioperative Anesthesia Care and Tumor Progression , 2017, Anesthesia and analgesia.

[19]  A. Tsung,et al.  Surgery for Cancer: A Trigger for Metastases. , 2017, Cancer research.

[20]  F. Bidard,et al.  Circulating tumor cells: clinical validity and utility , 2017, International Journal of Clinical Oncology.

[21]  Bongseog Kim,et al.  Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: a retrospective study , 2016, Korean journal of anesthesiology.

[22]  Kabir Mohammed,et al.  Long-term Survival for Patients Undergoing Volatile versus IV Anesthesia for Cancer Surgery: A Retrospective Analysis , 2016, Anesthesiology.

[23]  J. Orange,et al.  Practical NK cell phenotyping and variability in healthy adults , 2015, Immunologic Research.

[24]  V. Servois,et al.  Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. , 2015, Cancer letters.

[25]  L. Bergkvist,et al.  The choice of anaesthetic—sevoflurane or propofol—and outcome from cancer surgery: A retrospective analysis , 2014, Upsala journal of medical sciences.

[26]  Andreas Trumpp,et al.  Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients , 2014, BMC Cancer.

[27]  Tanja Fehm,et al.  Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.

[28]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[29]  P. Doran,et al.  Propofol and bupivacaine in breast cancer cell function in vitro - role of the NET1 gene. , 2014, Anticancer research.

[30]  T. Song,et al.  Propofol induces endoplasmic reticulum (ER) stress and apoptosis in lung cancer cell H460 , 2014, Tumor Biology.

[31]  Yan-bing Xu,et al.  Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-κB activity. , 2013, World journal of gastroenterology.

[32]  Jing Chen,et al.  Propofol inhibits invasion and enhances paclitaxel- induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug. , 2013, European review for medical and pharmacological sciences.

[33]  M. Gallucci,et al.  Immunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical Cystectomy: preliminary results , 2013, Journal of experimental & clinical cancer research : CR.

[34]  B. Faltas Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells , 2012, Front. Oncol..

[35]  Massimo Cristofanilli,et al.  Considerations in the development of circulating tumor cell technology for clinical use , 2012, Journal of Translational Medicine.

[36]  J. Lewis,et al.  Evaluation of a Flow Cytometry‐Based Assay for Natural Killer Cell Activity in Clinical Settings , 2012, Scandinavian journal of immunology.

[37]  Qingxiu Wang,et al.  Propofol reduces MMPs expression by inhibiting NF-κB activity in human MDA-MB-231 cells. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[38]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[39]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[40]  D. Moher,et al.  CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. , 2012, International journal of surgery.

[41]  Stefan Sleijfer,et al.  Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. , 2009, Cancer treatment reviews.

[42]  Mieke Schutte,et al.  Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.

[43]  G. Sauter,et al.  High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer , 2004, Breast Cancer Research and Treatment.

[44]  M. Gail,et al.  The promise and peril of surrogate end points in cancer research , 2002, Nature Reviews Cancer.

[45]  A. Schatzkin Intermediate markers as surrogate endpoints in cancer research. , 2000, Hematology/oncology clinics of North America.

[46]  D. Hedeker,et al.  Sample Size Estimation for Longitudinal Designs with Attrition: Comparing Time-Related Contrasts Between Two Groups , 1999 .

[47]  J. Schmitz,et al.  Determination of natural killer cell function by flow cytometry , 1996, Clinical and diagnostic laboratory immunology.